Thomas Steyer’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-26,000
| Closed | -$91.3K | – | 138 |
|
|
2026
Q1 | $91.3K | Hold |
26,000
| – | – | ﹤0.01% | 161 |
|
|
2025
Q4 | $71K | Hold |
26,000
| – | – | ﹤0.01% | 147 |
|
|
2025
Q3 | $56.4K | Hold |
26,000
| – | – | ﹤0.01% | 139 |
|
|
2025
Q2 | $44.7K | Hold |
26,000
| – | – | ﹤0.01% | 139 |
|
|
2025
Q1 | $86.6K | Hold |
26,000
| – | – | ﹤0.01% | 137 |
|
|
2024
Q4 | $192K | Hold |
26,000
| – | – | ﹤0.01% | 132 |
|
|
2024
Q3 | $244K | Hold |
26,000
| – | – | ﹤0.01% | 129 |
|
|
2024
Q2 | $209K | Hold |
26,000
| – | – | ﹤0.01% | 135 |
|
|
2024
Q1 | $385K | Sell |
26,000
-536,000
| -95% | -$6.24M | ﹤0.01% | 126 |
|
|
2023
Q4 | $4.57M | Buy |
+562,000
| New | +$2.94M | 0.02% | 93 |
|
|
2022
Q3 | – | Sell |
-3,176,773
| Closed | -$35.1M | – | 316 |
|
|
2022
Q2 | $35.1M | Sell |
3,176,773
-2,998,584
| -49% | -$39.3M | 0.19% | 78 |
|
|
2022
Q1 | $103M | Buy |
6,175,357
+113,384
| +2% | +$1.75M | 0.5% | 50 |
|
|
2021
Q4 | $116M | Buy |
6,061,973
+721,979
| +14% | +$15.9M | 0.58% | 44 |
|
|
2021
Q3 | $132M | Buy |
5,339,994
+89,994
| +2% | +$2.12M | 0.61% | 47 |
|
|
2021
Q2 | $137M | Buy |
5,250,000
+500,000
| +11% | +$13M | 0.56% | 46 |
|
|
2021
Q1 | $150M | Sell |
4,750,000
-1,250,000
| -21% | -$51.8M | 0.75% | 39 |
|
|
2020
Q4 | $278M | Buy |
6,000,000
+45,000
| +0.8% | +$1.79M | 1.67% | 25 |
|
|
2020
Q3 | $196M | Sell |
5,955,000
-582,500
| -9% | -$17.9M | 1.36% | 28 |
|
|
2020
Q2 | $179M | Buy |
6,537,500
+787,500
| +14% | +$25.9M | 1.44% | 27 |
|
|
2020
Q1 | $172M | Sell |
5,750,000
-500,000
| -8% | -$13.3M | 1.48% | 25 |
|
|
2019
Q4 | $173M | Buy |
6,250,000
+225,000
| +4% | +$5.12M | 1.17% | 30 |
|
|
2019
Q3 | $110M | Buy |
6,025,000
+300,000
| +5% | +$6.63M | 0.83% | 30 |
|
|
2019
Q2 | $140M | Hold |
5,725,000
| – | – | 0.91% | 30 |
|
|
2019
Q1 | $54.4M | Hold |
5,725,000
| – | – | 0.41% | 50 |
|
|
2018
Q4 | $50.7M | Buy |
5,725,000
+1,000,000
| +21% | +$9.64M | 0.37% | 46 |
|
|
2018
Q3 | $53.2M | Buy |
4,725,000
+300,000
| +7% | +$4.26M | 0.31% | 49 |
|
|
2018
Q2 | $56.6M | Buy |
4,425,000
+275,000
| +7% | +$4.02M | 0.35% | 48 |
|
|
2018
Q1 | $70.1M | Buy |
4,150,000
+2,283,100
| +122% | +$34.6M | 0.49% | 43 |
|
|
2017
Q4 | $14.9M | Buy |
1,866,900
+1,016,900
| +120% | +$8.16M | 0.12% | 61 |
|
|
2017
Q3 | $6.59M | Buy |
+850,000
| New | +$5.38M | 0.06% | 77 |
|
Other funds holding IOVA
MFM
PAI
Thomas Steyer's IOVA Position: Q2 2026 in Review
Thomas Steyer sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 26,000 shares — an estimated $91.3K sold.
Thomas Steyer first reported a position in IOVA in Q3 2017 and held it in 30 quarters. The position peaked at $278M in Q4 2020. 289 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.
- Thomas Steyer reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
- Thomas Steyer sold 26,000 Iovance Biotherapeutics shares in Q2 2026, an estimated $91.3K.
- Thomas Steyer first reported a position in Iovance Biotherapeutics in Q3 2017 and held it in 30 quarters.
- Thomas Steyer's Iovance Biotherapeutics position peaked at $278M in Q4 2020.
- 289 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.
Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.